$1.10
1.35% today
Nasdaq, Feb 28, 05:16 pm CET
ISIN
US9290331084
Symbol
VOR
Sector
Industry

Vor Biopharma Inc Stock price

$1.11
-0.28 20.14% 1M
+0.22 24.69% 6M
+0.00 0.00% YTD
-0.88 44.22% 1Y
-7.92 87.71% 3Y
-16.89 93.83% 5Y
-16.89 93.83% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.11 9.02%
ISIN
US9290331084
Symbol
VOR
Sector
Industry

Key metrics

Market capitalization $138.51m
Enterprise Value $108.55m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.04
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-118.00m
Free Cash Flow (TTM) Free Cash Flow $-99.89m
Cash position $62.81m
EPS (TTM) EPS $-1.65
P/E forward negative
Short interest 1.36%
Show more

Is Vor Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Vor Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Vor Biopharma Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Vor Biopharma Inc forecast:

Buy
100%

Financial data from Vor Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.64 3.64
60% 60%
-
-3.64 -3.64
60% 60%
-
- Selling and Administrative Expenses 22 22
58% 58%
-
- Research and Development Expense 89 89
2% 2%
-
-114 -114
1% 1%
-
- Depreciation and Amortization 3.64 3.64
60% 60%
-
EBIT (Operating Income) EBIT -118 -118
4% 4%
-
Net Profit -112 -112
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vor Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vor Biopharma Inc Stock News

Neutral
GlobeNewsWire
15 days ago
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. ...
Neutral
GlobeNewsWire
25 days ago
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference.
Neutral
GlobeNewsWire
about 2 months ago
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led ...
More Vor Biopharma Inc News

Company Profile

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Bob Ang
Employees 168
Founded 2015
Website www.vorbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today